Classified in: Health
Subjects: CCA, ACC

RaySearch Laboratories: Interim report January 1 - March 31, 2024

STOCKHOLM, May 17, 2024 /PRNewswire/ --

FIRST QUARTER (JANUARY - MARCH 2024)

Oder intake SEK 238.5 M (206.6)
Net sales SEK 257.2 M (230.2)
Operating profit SEK 45.8 M (23.7)
Profit after tax SEK 36.7 M (17.6)
Earnings per share before/after dilution SEK 1.07 (0.51)
Cash flow SEK 87.9 M (84.5)
Order backlog SEK 1,848.0 M (1,903.3) MSEK at the end of the period

SIGNIFICANT EVENTS DURING THE FIRTS QUARTER

RayStation in more than 1,000 radiotherapy centers worldwide.
The Royal Marsden set to be the first center in the world to implement online adaptive radiation therapy utilizing ARTemis from RaySearch.
RaySearch acquires the product DrugLog from Pharmacolog.
World leading carbon ion center QST in Chiba, Japan, selects RayStation.

SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD

Raigmore Hospital in Scotland selects RayCare.
RaySearch and C-RAD signed collaboration agreement.
RayCare has been certified to be interoperable with Varian TrueBeam.

WEBCAST

CEO Johan Löf and Interim CFO Annika Blondeau Henriksson will present RaySearch's interim report for January-March 2024 at a webcast to be held in English on Friday, May 17, 2024 at 10:00 a.m. CET.

Link to webcast: RaySearch Q1, 2024

You can also join the webcast by phone:
Sverige: +46 (0) 8 505 100 31
UK: +44 (0) 207 107 06 13
US: +1 (1) 631 570 56 13

The information contained in this interim report is such that RaySearch Laboratories AB (publ) is obliged to disclose under the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was submitted for publication on May 17, 2024 at. 7:45 a.m. CET.

For more information, please contact:
Johan Löf, founder and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0) 8 510 530 00
[email protected]

Annika Blondeau Henriksson, Interim CFO, RaySearch Laboratories AB (publ)
Telephone: +46 (0) 8 510 530 00
[email protected]

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/raysearch-laboratories/r/interim-report-january-1---march-31--2024,c3983281

The following files are available for download:

https://mb.cision.com/Main/1102/3983281/2803463.pdf

RaySearch Interim Report Q1 2024

SOURCE RaySearch Laboratories

These press releases may also interest you

at 05:23	ZINZINO AB (PUBL): PRELIMINARY SALES REPORT Q2 2024
	The revenue in June for Zinzino's sales markets increased by 13% and amounted to SEK 148.5 (131.4) million. Faun Pharma's external sales decreased and amounted to SEK 5.8 (8.5) million. Overall, the Group increased revenues by 10% to SEK 154.3...
at 05:00	Specialty Enzymes Market worth $9.2 billion by 2029 - Exclusive Report by MarketsandMarketstm
	The global Specialty Enzymes Market size is estimated to be valued at USD 6.1 billion in 2024 and is projected to reach USD 9.2 billion by 2029, recording a CAGR of 8.5% from 2024 to 2029 according to a report published by MarketsandMarketstm. The...
at 05:00	Danish start-up Kvantify secures EUR 10 million seed round to unlock quantum computing potential, starting with life sciences
	Kvantify, a leading quantum software start-up, has announced the successful closure of a EUR 10 million seed round. This funding will enable Kvantify to strengthen its position as a global leader in quantum computing, with an initial focus on...
at 04:37	Cytotoxic Drugs and HPAPI Manufacturing Market worth USD 27.1 Billion to 2031 - Exclusive Report by InsightAce Analytic
	InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Cytotoxic Drugs and HPAPI Manufacturing Market- (Type of Product (HPAPI and highly potent finished dosage form), Company Size (Small, Mid-sized, Large,...
at 04:32	Direct Primary Care Market Size to Reach USD 80.4 Billion by 2031- Latest Report by InsightAce Analytic Pvt. Ltd.
	InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Direct Primary Care Market"- By Type (Clinical Services, Telehealth Services, Laboratory Services, Consultative Services), Care Setting (Office-Based DPC...
at 04:32	High-Growth Industries with 25%-30% CAGR Growth Over the Next Five Years
	The Compound Annual Growth Rate (CAGR) measures how much an investment grows each year, on average, over a period. It helps to show the overall trend by smoothing out the ups and downs. Recently, BCC Research predicted that a certain industry would...
	More news about Health...

News published on 17 may 2024 at 01:54 and distributed by:

RaySearch Laboratories: Interim report January 1 - March 31, 2024

These press releases may also interest you

Le Lézard

Others sections

Follow us